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INTRODUCTION 
According to the World Health Organization, 350 and 170 mil-
lion are chronically infected with hepatitis B virus (HBV) and hepa-
titis C virus (HCV) infections, respectively.1,2 A further 15-20 mil-
lion people with HBV infection are co-infected with hepatitis delta 
virus (HDV). Central and Northern Asia are amongst the regions 
with the highest prevalence of HDV, which may infect up to 90% 
of HBV carriers in this region.3
Mongolia in central Asia is a unique country since all three 
chronic hepatitis viruses are highly endemic, as is infection from 
hepatitis A. As of July 2013, Mongolia had a population of just 3 
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million,4 a very low population density (1.8 people per km2) and a 
relatively young population age demographic with only 3.5% of 
people aged over 65 years.5 The country is classified geographi-
cally into regions comprising either urban or rural  locals.4,5 Ulaan-
baatar, the capital, is the largest city and is home to thirty-two 
percent of the nation’s population.4 
In a previous study,6 we reported on the prevalence of HBV, 
HDV and HCV infections in 110 consecutive patients presenting 
with acute hepatitis at eight city hospitals in Ulaanbaatar. In that 
study, 16.4%, 32.7%, 6.4%, 1.8%, and 27.3% of the patients 
were diagnosed as having acute hepatitis due to hepatitis A virus 
(HAV), HBV, HCV, HBV/HDV coinfection, and superinfection, re-
spectively.
Given the high prevalence of chronic viral hepatitis in Mongolia, 
not surprisingly, end stage liver disease and liver cancer are major 
cause of morbidity and mortality. Thus, the incidence of hepato-
cellular carcinoma is six times higher than the global average. 
Mortality in males in Mongolia is mainly due to cancers of the liv-
er and stomach; and in females, it is most commonly due to liver 
and cervical cancers.7-9
As Mongolia develops, with improvements in housing and sani-
tation, universal HBV vaccination, uniform screening of blood 
products, as well as improvements in infection control practices in 
hospitals and health centers, it would be expected that the num-
bers and prevalence of acute viral hepatitis should decline. In the 
present study conducted 10 years after our first report, the preva-
lence of acute HAV, HBV, HCV and HDV infections and their time 
trend changes were investigated. 
PATIENTS AND METHODS
Patient cohort
Consecutive patients clinically diagnosed as having acute viral 
hepatitis from January 2012 to December 2014, at the Depart-
ment of Infectious Diseases, National Center for Communicable 
Diseases, Mongolia, were studied. Patients were included if they 
fulfilled the following inclusion criteria: (1) an acute illness pre-
senting with signs or symptoms such as jaundice, dark urine, fa-
tigue, anorexia, nausea, vomiting and fever, and (2) a serum ala-
nine aminotransferase (ALT) level that was at least two and one-
half times the upper limit of normal. Patients were excluded if 
they had alcohol-related liver disease (determined by questioning 
of the patient and family members) and those with a history of 
exposure to hepatotoxic drugs or chemicals. Autoimmune liver 
disease was not positively excluded since testing for autoimmune 
markers was not available.
Approval of the study was obtained from the ethics committees 
of the Ministry of Health of Mongolia and from the Human Re-
search Ethics Committees of the Health Sciences University of 
Mongolia, Ulaanbaatar, Mongolia. The study was conducted in 
accordance with the international ethical guidelines of the Inter-
national Conference on Harmonization Guidelines for Good Clini-
cal Practice.10
Clinical and laboratory assessment
The following data were collected at the index diagnostic visit: 
sex, age, risk factor and routine laboratory tests. The latter, in-
cluding ALT, aspartate aminotransferase (AST) and bilirubin levels 
were determined by routine laboratory techniques. 
Serological and virological tests
Sera from the patients were tested for IgM antibody against 
HAV (anti-HAV IgM) and for total antibodies against HAV (anti-
HAV [total]) by enzyme-linked immunosorbentassay (ELISA) 
(HAM(N)-EIA and HAT-EIA, respectively; Denkaseiken, Tokyo, Ja-
pan). HBsAg was assessed by ELISA (IMxHBsAg Assay System; 
Abbott Japan, Tokyo, Japan); antibodies to HBsAg (anti-HBs) and 
antibodies to HBV core (anti-HBc [total]) was by passive hemag-
glutination with commercial assay kits (Mycell II anti-HBs and 
Mycell anti-HBc, respectively; Institute of Immunology Co. Ltd, 
Tokyo, Japan). Anti-HCV antibodies were assayed by the hemag-
glutination method (Abbott HCV-PHA; Abbott Japan). The pres-
ence of antibodies to HDV-IgM antibodies was determined by 
ELISA. Due to resource constraints, no other serological test or 
viral quantification was available. Serum HCV RNA was measured 
by a COBAS Amplicor HCV Test (Roche Diagnostics, Branchburg, 
NJ, USA) (<600 IU/mL).
Diagnosis of acute viral hepatitis
Acute hepatitis A infection was defined as positive anti-HAV 
IgM Ab, and acute hepatitis B was defined by a positive IgM anti-
HBc and circulating levels of HBsAg. Acute HCV infection was 
identified by positive HCV RNA in serum with either negative or 
positive anti-HCV antibody. Patients with negative anti-HCV anti-
body and positive HCV RNA were considered as acute hepatitis C 
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cases. Patients with positive anti-HCV antibody and positive HCV 
RNA were considered acute hepatitis C cases only if ALT values 
were >10 times upper limit of normal and there was a recent his-
tory of possible high-risk exposure to HCV (e.g., surgical proce-
dure). HBV/HDV co-infection was diagnosed by positive HDV-IgM 
antibodies in patient with acute hepatitis B (positive IgM anti-HBc 
and circulating levels of HBsAg), and acute HDV superinfection 
was defined by positive HDV-IgM antibodies in patients chronical-
ly infected with hepatitis B (positive IgG anti-HBc and HBsAg >6 
months).
Time trend analysis
We conducted a time trend analysis investigating the change in 
proportion of acute HCV, HBV and HDV infection among the cohort 
with respect to our previous study published a decade earlier.6
Statistical analysis
Quantitative data are expressed as mean±standard deviation 
(SD) and categorical data by number (percentage) of patients. For 
skewed variables, the data are presented as median and range. 
The Student t-test or non-parametric, i.e. Wilcoxon-Mann-Whit-
ney U-test or Kruskal-Wallis tests were used to compare quantita-
tive data, while appropriate. χ2 and Fisher-exact tests were used 
for the comparison of frequency data and to evaluate the relation-
ships between groups. All tests were two-tailed and P -values 
<0.05 were considered significant. All analyses were carried out 
using the statistical software package SPSS for Windows, version 
21 (SPSS Inc., Chicago, IL, USA).
RESULTS
The cohort comprised 546 consecutive patients with acute viral 
hepatitis. The mean age was 17.6 (SD, 10.3) years with 249 
(54.8%) male. The mean ALT at presentation was 1,800.6 IU/L 
(SD, 902.3), AST 1,152.4 IU/L (SD, 518.3) and total bilirubin 6.8 
mg/dL (SD, 3.1). The characteristics of the cohort are shown in 
Table 1.
Etiology of acute hepatitis
Acute hepatitis A (anti-HAV IgM-positive) was diagnosed in 278 
(50.9%), acute hepatitis B (anti-HBc IgM-positive and 6 months 
follow-up HBsAg negative) in 143 (29.2%) and acute hepatitis C 
in 33 (6.0%) patients. Ninety two (16.8%) patients had either co-
infection or super-infection with two hepatitis viruses. 
Table 1. Comparison of the characteristics of the different acute hepatitis (A, B and C) virus infection
Feature
  Total                        
(n=454)
Acute hepatitis A 
(n=278)
Acute hepatitis B   
(n=143)
Acute hepatitis C 
(n=33)
P-value
Age (years) 17.6±10.3 11.6±5.9 22.9±5.2 32.2±10.3 <0.001
Male 249 (54.8) 149 (53.6) 84 (58.7) 16 (48.5) 0.311
Risk factors*
Blood transfusion 16 (3.5) 1 (0.4) 9 (6.3) 6 (18.2) <0.001
Tattooing 53 (11.7) 3 (1.1) 48 (33.6) 2 (6.1) <0.001
Surgery 74 (16.3) 8 (2.9) 47 (32.9) 19 (57.6) <0.001
Dental care 102 (22.5) 7 (2.5) 78 (54.5) 17 (51.5) <0.001
Acupuncture 9 (2.0) 0 9 (6.3) 0 <0.001
Family history 17 (3.7) 3 (1.1) 13 (9.1) 1 (3.0) 0.004
Laboratory data
Total bilirubin (mg/dL) 6.8±3.1 4.5±2.4 7.3±3.1 6.3±3.9 <0.001
ALT (IU/L) 1800.6±902.3 1537±651.7 2250.5±782.0 1719.3±997.2 <0.001
AST (IU/L) 1152.4±518.3 973.5±450.8 1160.1±412.8 1021.4±621.5 <0.001
Values are presented as mean±SD or n (%). Post Hoc analysis “Bonferroni” was applied. 
ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
*Survey of risk factors allowed duplication.  
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Comparison of the characteristics of patients with 
acute hepatitis
The mean age of patients infected with acute hepatitis A was 
lower than those with acute hepatitis B or C (11.6±5.9, 22.9±5.2 
and 32.2±10.3, respectively, P<0.001) (Table 1). Hepatitis A was 
the most prevalent cause of acute viral hepatitis among 2-19 year 
olds, while acute hepatitis B and superinfection with HDV were 
the most prevalent causes among the 20-40 year age group. In-
terestingly, hepatitis C was the most prevalent acute viral hepati-
tis among 40-49 year old patients (Table 2). We did not observe 
differences in the prevalence of acute hepatitis when stratified ac-
cording to gender.
The AST, ALT and bilirubin levels at presentation were signifi-
cantly higher among patients with acute hepatitis B than among 
those with acute hepatitis C or A (P<0.001, for all) (Table 1). 
Blood transfusion and surgery were significantly more frequent 
as possible risk factors for acute hepatitis C acquisition (P<0.001), 
while patients with acute hepatitis B were more likely to have one 
or more of the possible risk factors for acquiring blood-borne 
hepatitis viruses, including tattooing, dental care, or folk remedies 
such as acupuncture and bloodletting within 6 months before the 
onset of disease or being a health care worker. Patients with 
acute hepatitis B were significantly more likely to have tattooing 
and family histories of hepatitis as risk factors than those with 
acute hepatitis C or A (P<0.001, for both) (Table 1).
Table 2. Age-dependent prevalence of acute viral hepatitis in Mongolia
Age 
(years)
No. of 
patients
Acute hepatitis A Acute hepatitis B Acute hepatitis C 
Coinfection of 
HBV and HDV
Superinfection of   
HDV    
2-9 118 116 (95.1) 2 (1.4) 0 0 0
10-19 156 123 (70.7) 24 (16.8) 5 (2.9) 1 (0.6) 3 (1.7)
20-29 214 39 (14.9) 100 (69.9) 8 (3.1) 23 (8.8) 44 (16.8)
30-39   45 0 17 (11.9) 12 (24.0) 8 (16.0) 8 (16.0)
40-49   13 0 0 8 (50.0) 1 (6.3) 4 (25.0)
Total 546 278 (50.9) 143 (26.2) 33 (6.0) 33 (6.0) 59 (10.8)
Values are presented as n (%).  
HBV, hepatitis B virus; HDV, hepatitis delta virus. 
Table 3. Comparison of baseline characteristics of patients with mono-infection and those with coinfection or superinfection
Feature
Acute hepatitis (A, B or  C)
(n=454)
Coinfection or superinfection 
(n=92)
P-value
Mean age±SD (years) 17.6±10.3 24.8±7.0 <0.001
Male 249 (54.8) 66 (71.7) 0.030
Risk  factors
Blood transfusion 16 (3.5) 11 (12.0) <0.001
Tattooing 53 (11.7) 33 (35.9) <0.001
Surgery 74 (16.3) 43 (46.7) <0.001
Dental care 102 (22.5) 44 (47.8) <0.001
Acupuncture 9 (2.0) 4 (4.3) 0.008
Family history 17 (3.7) 15 (16.3) <0.001
Laboratory data
Total bilirubin (mg/dL) 6.8±3.1 9.4±4.8 <0.001
ALT (IU/L) 1,800.6±902.3 2,432.1±1128.1 <0.001
AST (IU/L) 1,152.4±518.3 1,731.5±1365.1 <0.001
Values are presented as mean±SD or n (%).  
ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
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Comparison of the characteristics of patients with 
acute hepatitis of co and super-infection
Of the overall cohort, 92 (16.8%) patients had either co-infec-
tion or super-infection with two hepatitis viruses. There were 59 
(10.8%) patients who had detectable HBsAg and anti-HDV but 
who were negative for both IgM anti-HAV and IgM anti-HBc, sug-
gesting that they had developed superinfection with HDV. Unfor-
tunately, HBeAg status was not known, due to lack of testing re-
sources, nor was HDV RNA testing available. Thus, in this group, 
it is not possible to definitely exclude HBV reactivation in a HBV-
HDV co-infected patient. 
Patients with more than one hepatitis virus infection were signifi-
cantly older, more likely to be male and had a higher prevalence of 
all risk factors for disease acquisition. These patients also had more 
severe liver disease at presentation with higher AST, ALT and biliru-
bin levels compared to those with mono-infection (Table 3).
Those with superinfection of HDV had higher bilirubin levels 
than all other types of co- and superinfection, and were signifi-
cantly more likely to be male. No difference in risk factors was ob-
served between different groups (Table 4).
Time trend analysis
We undertook time trend analysis between our initial study 
published in 2006, and the present cohort (2012-2014). As shown 
in Fig. 1, we observed a significant decline in the proportion of 
HDV superinfection (from 27% to 11%, P=0.001), while those of 
acute HCV and HBV infection changed from 6% to 6% and from 
33% to 26%, respectively. There was a significant increase in the 
incidence of acute hepatitis A (from 16% to 26%, P<0.001).
DISCUSSION
We have described the epidemiology of acute viral hepatitis in 
Mongolia between 2012 and 2014. We also undertook time trend 
analysis with similar data obtained a decade earlier and previously 
Table 4. Comparison of characteristics between co-infection and superinfection of HBV and HDV 
Feature
Total
(n=92)
Co-infection of HBV and 
HDV (n=33)
Superinfection of HDV on 
HBV (n=59)
P-value
Mean age±SD (years) 24.8±7.0 26.48±6.33 25.94±6.78 0.001
Male 66 (71.7) 20 (60.6) 46 (78.0) 0.004
Risk factors
Blood transfusion 11 (12.0) 3 (9.1) 8 (13.6) 0.001
Tattooing 33 (35.9) 14 (42.4) 19 (32.2) <0.001
Surgery 43 (46.7) 16 (48.5) 27 (45.8) <0.001
Dental car 44 (47.8) 17 (51.5) 27 (45.8) <0.001
Acupuncture 4 (4.3) 1 (3.0) 3 (5.1) <0.001
Family history 15 (16.3) 4 (12.1) 11 (18.6) <0.001
Laboratory data
Total bilirubin (mg/dL) 9.4±4.8 8.69±3.52 10.62±5.25
ALT (IU/L) 2,432.1±1,128.1 2753.9±1,540.8 2,704.3±1,508.2 0.504
AST (IU/L) 1,731.5±1,365.1 1892.8±1187.5 1,962.9±1,258.9 0.005
Values are presented as mean±SD or numbers (%).  
HBV, hepatitis B virus; HDV, hepatitis delta virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
Figure 1. Changes in the proportion of acute hepatitis A, B, C and D in 
Mongolia. HAV, hepatitis A virus; HBV, hepatitis B virus; HDV, hepatitis del-
ta virus; HCV, hepatitis C virus.
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published.6 The most important outcome of the present study is 
the knowledge that Mongolia still has an ongoing epidemic of 
acute viral hepatitis. Despite significant changes in socioeconomic 
parameters, for example, increasing school enrollment by 117% 
from 1994 to 2012 and an increase in Gross National Income per 
capita, from 0.3 to 3.77 US dollars,11 the epidemic of acute viral 
hepatitis remains largely not decreased. Thus, apart from HDV in-
fection, there was no significant decline in the number of cases 
with acute hepatitis due to the other viruses, and there was a sig-
nificant increase in HAV infection.
The clinical illness in Mongolia is manifested across essentially 
all population groups, attesting to the pervasive nature of the epi-
demic, something that is by and large nonexistent in most other 
parts of the world. Notably, 16.8% of patients presented with ei-
ther co-infection or super-infection with two hepatitis viruses, a 
clinical scenario that is rare in developed nations. As expected, 
those with more than one infection had clinically more severe dis-
ease at presentation manifested by higher levels of ALT, AST and 
serum bilirubin.
Despite being a major cause of acute hepatitis in many coun-
tries,11 the relative contribution of injecting drug use (IDU) to viral 
hepatitis burden in Mongolia was significantly lower than in other 
regions. In an international study including 57 countries, HCV 
prevalence was reported to be at least 50% among IDUs in 49 
countries. However, available regional estimates varied widely; it 
was up to 96% in Eastern Europe and Central Asia, 93% in East-
Asia and the Pacific, between 25 to 88% in Australia and New 
Zealand, and from 2 to 93% in Western Europe.12 In our study, 
IDU was virtually nonexistent. In Mongolia, viral hepatitis trans-
mission is mainly associated with medical exposures (dental care, 
surgery and blood transfusion), which were responsible for 40% 
of all infections. Blood transfusion and surgery were more preva-
lent risk factors among patients with acute HCV, while tattooing, 
dental care, acupuncture and bloodletting were the main risk fac-
tors for acute hepatitis B (Table 1). No difference in risk factors 
was observed among the different categories of patients with 
more than one infection (Table 4).
The results of our time trend analysis suggest that there are 
varying rates of decline of the three blood-borne hepatitis viruses 
(HBV, HCV, and HDV). While there was a dramatic decline in HDV 
superinfection (27.3% to 10.8%, P=0.001) over the last decade, 
contrary to expectations, there appeared to only be a small de-
cline (32.7% to 26.2%, and 6.4% to 6.0%, respectively) in HCV 
and HBV incidence over time (Fig. 2). There were just 26 cases of 
acute HBV infection in the 0-19 age group in the present cohort. 
In Mongolia, mass hepatitis B vaccination program was initiated 
in 1991 with 98-100% of all live babies receiving vaccination 
within 24-48 hours after birth. However, even today, there is no 
universal testing of blood in all centers since patients have to pay 
for blood screening. Thus, the influx of uninfected birth cohorts, 
and improved medical hygiene may partially explain the small de-
cline in HCV and HBV incidence.
Unexpectedly, there was a significant increase in the incidence 
of acute HAV infection compared to our previous study (from 
16.4% to 50.9%, P<0.001). This observation is not completely 
explained; however, it may reflect community outbreaks as previ-
ously reported in 2007.13 Another possibility is that parents are 
now more aware when children develop acute hepatitis and 
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therefore seek medical advice. Thus, the increase in the propor-
tion of cases attributable to HAV may represent a change in the 
percentage of cases seeking medical attention rather than chang-
es in overall disease incidence. This is also consistent with data 
from a large survey of 520 apparently healthy 7-12 year olds, sug-
gesting that the prevalence of anti-HAV antibodies in Mongolia is 
85%.14 
This study has also limitations as an epidemiologic study. In ad-
dition, it is sometimes hard to recognize the exact timing of infec-
tion such as HCV infection. Our findings clearly suggest that much 
more rigorous and stringent infection control public health poli-
cies and measures are required across Mongolia to eliminate inci-
dent acute viral hepatitis. Many of these policies are easy to imple-
ment including basic infection control practices across medical and 
dental facilities, as well as, for example, the use of single use nee-
dles, syringes and equipment during acupuncture or tattooing. 
While local resource limitations are an issue, international health 
agencies can provide much-needed expertise and help to construct 
and implement policies to reduce viral hepatitis transmission.
We agree that only a national epidemiologic study can provide a 
definitive answer regarding the overall prevalence and incidence of 
viral hepatitis and dynamic trends over time in Mongolia. Lacking 
such a national sample survey, our study from the national viral 
hepatitis treatment center provides a useful secondary measure.
In conclusion, acute viral hepatitis is still prevalent in Mongolia. 
There is an urgent need for efforts to improve infection control 
measures in the medical system. The results from this large cohort 
of patients with acute hepatitis in the National Center for Com-
municable Diseases in Ulaanbaatar, Mongolia, will improve our 
understanding of current measures for hepatitis control, and sug-
gest where new resources need to be deployed.
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